Drugmaker Granules India’s step-down subsidiary Granules Consumer Health Inc. (GCH) has completed an audit by the U.S. Food and Drug Administration (U.S. FDA) with zero observations.

Granules arm completes U.S. FDA audit

Granules India gained 2.24% to Rs 288.15 after the drug maker said that its step-down subsidiary, Granules Consumer Health Inc has completed the United States Food and Drug Administration (USFDA) audit with zero observations.

Granules India rises after arm clears USFDA audit

Granules Consumer Health’s packaging unit in Manassas was inspected by the US FDA from March 15-20.

Granules India shares rise as arm concludes US FDA audit

The drug is indicated for treatment of hypertension in adults and paediatric patients 6 years of age and older

Granules India gets USFDA nod for hypertension drug

Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic product to treat high blood pressure.

Granules gets USFDA nod to market generic medicine for high blood pressure

The company has received approval from the US Food & Drug Administration (USFDA) to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg, Granules India said in a regulatory filing.

Granules gets USFDA nod to market generic medication to treat high blood pressure

The pharmaceutical company announced that it has received approval from US Food and Drug Administration (USFDA) for its abbreviated new drug and application (ANDA) for Losartan Potassium tablets.

Granules India gets USFDA nod for Losartan Potassium tablets

The company now has a total of 54 ANDA approvals from USFDA, including 52 final approvals and 2 tentative approvals.

Granules India secures FDA nod to hypertension drug but share price falls

It is bioequivalent to the reference listed drug product (RLD), Cozaar Tablets of Organon LLC.

Granules India receives USFDA approval for Losartan Potassium Tablets

Granules India: The US Food & Drug Administration (US FDA) has approved the drug maker’s Abbreviated New Drug Application (ANDA) for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg. It is bioequivalent to the reference listed drug product

Granules India, Power Grid Corp, Marico, SpiceJet in spotlight

Stocks to watch: Shares of firms like IndiGo, SpiceJet, IOC, Paytm, Vodafone Idea, Granules India, and others will be in focus in Monday’s trade.

Stocks to Watch: IndiGo, SpiceJet, IOC, Paytm, Vodafone Idea, Granules India, and Others

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Granules India Limited is a pharmaceutical company that manufactures finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).